2026-07-04 · SGLT2 inhibitors, empagliflozin, dapagliflozin, canagliflozin, type 2 diabetes, heart failure, chronic kidney disease · 19 min read
Written by Nora Kim
Nora Kim covers medical and surgical weight loss options, GLP-1 therapies, and evidence-based supplements. She focuses on explaining clinical research, safety considerations, and practical next steps so readers can discuss treatment choices with their care teams.
SGLT2 Inhibitors and Weight: What Jardiance, Farxiga, and Invokana Actually Do to the Scale
Sodium-glucose cotransporter 2 (SGLT2) inhibitors — empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), ertugliflozin (Steglatro), bexagliflozin (Brenzavvy) — are one of the two drug classes that reshaped diabetes and cardiorenal medicine in the last decade. Cai 2018 (Obesity), the largest meta-analysis of weight change on the class, pooled a placebo-adjusted mean weight loss of about 1.8 kg with a typical range of 1 to 3 kg. Bolinder 2012 (Journal of Clinical Endocrinology and Metabolism) confirmed with DXA that the change is predominantly subcutaneous and visceral fat mass, not fluid or lean mass. But that scale change is not why these drugs exist in the modern formulary.
The reason SGLT2 inhibitors are first-line agents in type 2 diabetes with established or high-risk atherosclerotic cardiovascular disease, in heart failure with reduced or preserved ejection fraction regardless of diabetes, and in chronic kidney disease with eGFR of at least 20 regardless of diabetes is the cardiorenal outcome data — Zinman 2015 EMPA-REG OUTCOME (NEJM), McMurray 2019 DAPA-HF (NEJM), Packer 2020 EMPEROR-Reduced (NEJM), Solomon 2022 DELIVER (NEJM), Perkovic 2019 CREDENCE (NEJM), Heerspink 2020 DAPA-CKD (NEJM), and The EMPA-KIDNEY Collaborative Group 2023 (NEJM). The ADA 2024 Standards of Care, the ESC 2023 Heart Failure Guideline update, and KDIGO 2024 all position SGLT2 inhibitors as first-line disease-modifying therapy in the appropriate indication. Roughly 1.8 kg of fat loss is a welcome side effect, not the target.
This guide covers who benefits, how the class works, dose and titration, the diabetic-ketoacidosis and genital-mycotic safety issues that require honest patient education, and how SGLT2 inhibitors sit alongside metformin, GLP-1 receptor agonists, and modern four-pillar heart-failure therapy.
Quick stats
- Cai 2018 placebo-adjusted mean weight loss on the class: about 1.8 kg (typical range 1 to 3 kg), plateauing by 24 weeks (Obesity).
- EMPA-REG OUTCOME all-cause mortality: –32% on empagliflozin vs placebo in type 2 diabetes with established cardiovascular disease (Zinman 2015, NEJM).
- DAPA-HF and EMPEROR-Reduced: –26% and –25% primary composite (HF hospitalization or CV death) in HFrEF regardless of diabetes (McMurray 2019; Packer 2020).
- DAPA-CKD kidney-failure endpoint: –39% on dapagliflozin in CKD regardless of diabetes (Heerspink 2020).
- Genital mycotic infection incidence: 5 to 10% across trials; usually treated topically; rarely a reason to discontinue.
- 911 red flag: new abdominal pain with nausea or vomiting (check ketones — euglycemic DKA); perineal pain, redness, or crepitus (Fournier’s gangrene).
- 1-800-222-1222 — US Poison Control for accidental over-ingestion in a child or adult.
How SGLT2 inhibitors are organised
Five SGLT2 inhibitors are approved in the US as of 2026. All share the same core mechanism — blocking sodium-glucose cotransporter 2 in the proximal tubule of the kidney so filtered glucose spills into urine — but they differ in the depth of their outcome-trial evidence.
| Drug | Typical dose | Strongest indication | Key trials |
|---|---|---|---|
| Empagliflozin (Jardiance) | 10 to 25 mg daily | T2D + ASCVD; HFrEF and HFpEF; CKD | EMPA-REG, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY |
| Dapagliflozin (Farxiga) | 5 to 10 mg daily | HFrEF and HFpEF; CKD; T2D + risk | DECLARE-TIMI 58, DAPA-HF, DELIVER, DAPA-CKD |
| Canagliflozin (Invokana) | 100 to 300 mg daily | T2D + CKD; T2D + ASCVD | CANVAS, CREDENCE (historical amputation signal) |
| Ertugliflozin (Steglatro) | 5 to 15 mg daily | T2D glycemic control | VERTIS-CV (neutral on primary MACE) |
| Bexagliflozin (Brenzavvy) | 20 mg daily | T2D glycemic control | Limited outcome data |
Empagliflozin and dapagliflozin dominate current prescribing because they hold the strongest and broadest outcome evidence. Canagliflozin retains a role in CKD with type 2 diabetes based on CREDENCE. Ertugliflozin and bexagliflozin are less commonly used and lack the same cardiorenal outcome depth.
Why SGLT2 inhibitors work (and don’t) for weight
Four mechanistic threads describe how SGLT2 inhibitors change body weight, and one describes why the effect plateaus at about 2 kg.
1. Glucosuria and caloric loss
Ferrannini 2016 (Journal of Clinical Investigation) quantified the primary mechanism: SGLT2 blockade dumps roughly 200 to 320 kcal per day of glucose into the urine at typical A1c. That is a modest but consistent negative energy draw — enough to lose 20 to 30 pounds per year on paper. In practice, actual weight loss is much smaller because the ceiling drops as A1c falls (less glucose to spill) and because appetite compensates.
2. Compensatory hyperphagia
Ferrannini 2015 (Diabetes Care) documented the reason weight plateaus. Appetite rises modestly as the body senses the calorie loss, and food intake partially replaces the urine glucose. The behavioral counterweight is the reason 1.8 kg is a realistic long-term expectation rather than 10 kg. This is not a failure of the drug — it is why SGLT2 inhibitors are safe on top of normal eating, not a starvation therapy.
3. Fat-mass, not fluid-mass, loss
Bolinder 2012 (JCEM) used DXA to characterize body-composition change on dapagliflozin 10 mg for 24 weeks. Roughly 65 to 75% of the weight change came from subcutaneous and visceral fat, not from water. There is a small osmotic-diuresis component in the first two weeks — probably 0.5 to 1 kg — that stabilizes as the body adjusts. Do not confuse SGLT2 inhibitors with loop or thiazide diuretics; after the first two weeks, the weight loss is real fat.
4. What SGLT2 inhibitors are not
SGLT2 inhibitors are not GLP-1 receptor agonists (the weight loss is roughly half the size and about one-fifth the size of tirzepatide), not a substitute for a calorie deficit or structured activity, and not appropriate as a stand-alone obesity drug. The mean 1.8 kg effect is smaller than the difference between two water-weight days, and anyone expecting semaglutide- or tirzepatide-scale weight loss will be disappointed. Anyone using an SGLT2 inhibitor for diabetes, heart failure, or kidney disease has a durable cardiorenal drug with modest weight loss as a bonus.
Dose-response and time-course
The weight and A1c effects front-load, plateau by 24 weeks, and hold thereafter. Cardiorenal outcome curves separate from placebo within the first six to 12 months and continue to diverge for years.
| Timepoint | Weight change vs baseline | A1c change | Cardiorenal signal |
|---|---|---|---|
| 2 weeks | –0.5 to –1.0 kg (mostly osmotic) | Small decline | Early diuretic effect in HF |
| 8 weeks | –1.0 to –1.5 kg | –0.5 to –0.7% | Not yet visible |
| 24 weeks | –1.5 to –2.0 kg (plateau, Bolinder 2012) | –0.7 to –1.0% | Early HF hospitalization separation |
| 12 months | –1.8 to –2.5 kg (Cai 2018 pooled) | Sustained | Renal and HF outcome curves separating |
| 24 months | Plateau near –2 kg | Sustained | MACE reduction stable in EMPA-REG at 3.1 y |
| 36 months | Plateau maintained | Sustained | –32% mortality reduction (EMPA-REG); –26% HF composite (DAPA-HF) |
5-step protocol: screening, initiation, and monitoring
This is the practical clinical rhythm most prescribers follow in 2026. It matches ADA 2024 Section 9 and Section 10, ESC 2023, and KDIGO 2024.
Step 1: Confirm the indication
SGLT2 inhibitors are first-line for type 2 diabetes with established or high risk of ASCVD, HF, or CKD (ADA 2024), for heart failure with reduced or preserved ejection fraction regardless of diabetes (ESC 2023 Class I recommendation), and for chronic kidney disease with eGFR of at least 20 regardless of diabetes (KDIGO 2024). Type 2 diabetes without cardiovascular or renal comorbidity is also an appropriate indication, but the case for choosing an SGLT2 inhibitor over metformin monotherapy is weaker in this population.
Step 2: Baseline labs and volume-status check
Before starting, most prescribers check eGFR and urine albumin-to-creatinine ratio, a comprehensive metabolic panel including electrolytes, and hydration status. Do not initiate in adults with eGFR below 20 (KDIGO 2024 continuation may be acceptable if the drug was already tolerated). Assess volume status carefully in older adults on loop diuretics — initial diuresis can compound existing volume depletion. Document any history of recurrent genital mycotic infection, prior DKA, ketogenic-diet adherence, planned surgery, or opioid or immunosuppressive therapy that might increase Fournier’s gangrene risk.
Step 3: DKA safe-start education
The single most important teaching point is euglycemic diabetic ketoacidosis. Douros 2020 (Annals of Internal Medicine) documented an incidence of roughly 0.1 percent per year overall, higher in type 1 diabetes and on ketogenic or very-low-carb diets. Teach: hold the drug 3 to 4 days for scheduled surgery, longer for major procedures; avoid the combination with a ketogenic diet; check ketones on any abdominal pain, nausea, vomiting, or fruity breath — even if blood glucose is normal or only mildly elevated. See our companion guides on low-carb keto diets and type 1 diabetes and weight loss for the fuller context.
Step 4: Genital-mycotic hygiene counselling
Baseline incidence of genital mycotic infection is 5 to 10 percent across the class, higher in women and uncircumcised men, and easily treated with topical antifungals. This is almost never a reason to discontinue permanently. Practical counselling includes daily gentle hygiene, prompt treatment of symptoms, and reassurance that recurrence rates drop after the first six months. Recurrent or severe infection is a signal to reassess the risk-benefit calculation.
Step 5: Monitor A1c, eGFR, and volume status
Follow ADA 2024 for glycemic monitoring — A1c at 3 months, then every 6 months. Follow KDIGO 2024 for renal monitoring — eGFR and urine albumin-to-creatinine ratio at 3 months, then every 6 to 12 months. Hold the drug for acute illness with dehydration or reduced oral intake, and hold peri-procedurally. Do not stop for a small eGFR dip in the first 4 weeks — an initial 5 to 10% functional decline is expected and reverses; the long-term slope is protective.
Treatment comparison table
The honest comparison across the modern diabetes and cardiorenal formulary. Weight-loss effect is placebo-adjusted at 12 months where available.
| Drug class | Weight effect | A1c effect | MACE | HF hospitalization | CKD progression | Hypoglycemia risk |
|---|---|---|---|---|---|---|
| SGLT2 inhibitors | –1.5 to –3 kg | –0.7 to –1.0% | Reduction (EMPA-REG, CANVAS) | Reduction (DAPA-HF, EMPEROR, DELIVER) | Reduction (CREDENCE, DAPA-CKD, EMPA-KIDNEY) | Very low alone |
| GLP-1 receptor agonists | 10 to 22% of body weight | –1.0 to –2.0% | Reduction with semaglutide (SELECT) | Neutral to modest | Reduction (FLOW trial) | Very low alone |
| Metformin | –2 to –3 kg (DPP) | –1.0 to –1.5% | Reduction (UKPDS 34) | Neutral | Neutral | Very low |
| DPP-4 inhibitors | Neutral | –0.5 to –0.8% | Neutral | Neutral (small saxagliptin signal) | Neutral | Very low |
| Sulfonylureas | +2 to +3 kg | –1.0 to –1.5% | Neutral | Neutral | Neutral | Substantial |
| Basal insulin | +1 to +4 kg | Dose-dependent | Neutral | Neutral | Neutral | Present |
Heart failure regardless of diabetes
The four-pillar HFrEF guideline-directed medical therapy era changed heart-failure prescribing. Vaduganathan 2022 (Lancet) formalized the “four pillars” — ARNI (sacubitril-valsartan), beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor — as standard care for heart failure with reduced ejection fraction.
The pillar drugs work in the following order in most modern practice. McMurray 2019 DAPA-HF (NEJM) established dapagliflozin as a 26% relative reduction in worsening HF or CV death in HFrEF regardless of diabetes. Packer 2020 EMPEROR-Reduced (NEJM) matched the signal with empagliflozin at 25%. Anker 2021 EMPEROR-Preserved (NEJM) and Solomon 2022 DELIVER (NEJM) extended the benefit to heart failure with preserved ejection fraction — a 21% and 18% relative reduction respectively — closing a treatment gap that had persisted for two decades. Nassif 2021 EMPULSE and SOLOIST-WHF confirmed the safety of inpatient initiation.
The ESC 2023 Heart Failure Guideline update made SGLT2 inhibitors a Class I recommendation across HFrEF, HFmrEF, and HFpEF. Anyone reading this article for a heart-failure indication should not delay initiation over 1.8 kg of weight loss — the outcome benefit is the point. See our companion guide on heart failure and weight loss for the fuller framework.
Chronic kidney disease regardless of diabetes
The CKD era paralleled the HF era. Perkovic 2019 CREDENCE (NEJM) established canagliflozin as a 30% relative reduction in the composite renal endpoint in diabetic kidney disease. Heerspink 2020 DAPA-CKD (NEJM) extended the benefit to CKD regardless of diabetes with a 39% relative reduction in kidney-failure endpoints — a signal so strong the trial was stopped early. The EMPA-KIDNEY Collaborative Group 2023 (NEJM) confirmed the class effect in an even broader CKD population, including patients without albuminuria and with lower eGFR.
KDIGO 2024 now positions SGLT2 inhibitors as first-line disease-modifying therapy in CKD with eGFR of at least 20, regardless of diabetes status. The threshold for initiation is eGFR 20; the threshold for continuation is generally lower — a prescriber decision informed by the individual trial protocols. See chronic kidney disease and weight loss for the fuller CKD framework and diabetes and weight loss for the diabetes-specific lens.
Type 2 diabetes with atherosclerotic cardiovascular disease
The trial that started the modern SGLT2 story was Zinman 2015 EMPA-REG OUTCOME (NEJM). Empagliflozin cut 3-point MACE by 14% and all-cause mortality by 32% in type 2 diabetes with established cardiovascular disease over 3.1 years. Neal 2017 CANVAS (NEJM) confirmed a similar signal with canagliflozin (14% MACE reduction) but flagged a lower-limb amputation signal that shaped canagliflozin prescribing for several years — the signal has since been reassessed as smaller than initially reported. Wiviott 2019 DECLARE-TIMI 58 (NEJM) tested dapagliflozin in a broader T2D primary-prevention population and reported a 27% reduction in heart-failure hospitalization without a significant MACE reduction — reframing dapagliflozin as an HF-first drug rather than a MACE-first drug.
Neuen 2020 (Circulation) pooled the cardiorenal outcomes across CANVAS, CREDENCE, and DECLARE and confirmed the class effect. ADA 2024 Section 10 now positions SGLT2 inhibitors as first-line-with-metformin for T2D with established or high risk of ASCVD, HF, or CKD — the largest single formulary shift in T2D prescribing in a generation. See metformin and weight for the partner drug’s story.
Type 1 diabetes and off-label use
DKA risk is sharply higher in type 1 diabetes because there is less endogenous insulin to suppress ketone production. Douros 2020 documented a several-fold increase in DKA risk when SGLT2 inhibitors were used in type 1 diabetes, and the FDA has not approved any SGLT2 inhibitor for type 1 diabetes in the US. European regulators approved low-dose dapagliflozin for type 1 diabetes with careful patient selection but subsequently withdrew the indication over the DKA signal. If you have type 1 diabetes and your endocrinologist is considering off-label SGLT2 inhibitor therapy, ketone-strip monitoring at home, sick-day rules, and an explicit DKA action plan are non-negotiable. See type 1 diabetes and weight loss for the fuller framing.
SGLT2 inhibitors plus GLP-1 receptor agonists
The combination is common and increasingly first-line for adults with type 2 diabetes and cardiovascular or renal comorbidity. There is no clinically important pharmacokinetic interaction, weight and A1c effects are additive, and the cardiorenal signals compound. Both drug classes reduce appetite through different pathways — GLP-1 through hindbrain and gastric-emptying effects, SGLT2 inhibitors through caloric loss — and the net weight-loss effect approximates the sum of the two. GI side-effect burden also stacks, so most prescribers hold SGLT2 titration until the GLP-1 is at a tolerated dose. See GLP-1 medications compared, semaglutide weight loss, and tirzepatide weight loss for the GLP-1 side of the combination.
SGLT2 inhibitors on a ketogenic or very-low-carb diet
This is the single most important safety warning in the article. Ketogenic and very-low-carb diets push the body toward fat-burning and ketone production; SGLT2 inhibitors accelerate the same process. Stacked, they can drive euglycemic diabetic ketoacidosis — DKA at normal blood glucose, without the usual warning sign of hyperglycemia. Douros 2020 and multiple FDA post-marketing reports document the pattern.
The rule is simple: choose one — the diet or the drug — but not both. If you are on a ketogenic diet and being considered for an SGLT2 inhibitor, discuss switching to a GLP-1 receptor agonist, metformin, or another glucose-lowering agent, or shift your nutrition to a moderate-carb Mediterranean-style pattern before starting. If you are already on an SGLT2 inhibitor and considering a ketogenic diet, discuss the trade-off with your prescriber first. See low-carb keto diets for the diet context.
Genital mycotic infections and Fournier’s gangrene
Genital mycotic infections in 5 to 10 percent of users are the most common tolerability issue with the class — usually treated topically and rarely a reason to discontinue. Recurrence rates drop after the first six months, and daily hygiene and prompt topical antifungal treatment resolve the vast majority of cases.
Fournier’s gangrene — a rapidly progressive polymicrobial infection of the perineum and genitalia — is rare but serious, and the FDA added a class-wide warning in 2018. Presenting features are perineal or genital pain, redness, swelling, fever, and progression over hours. Anyone with these symptoms on an SGLT2 inhibitor should stop the drug immediately and go to the emergency room. Delayed presentation carries substantial morbidity and mortality.
Red flags — when to see a doctor
Some findings are not routine and warrant same-week or same-day evaluation.
- New abdominal pain with nausea, vomiting, or fruity breath — check ketones; 911 or ER for confirmed ketosis with acidosis, even if blood glucose is normal (euglycemic DKA).
- Perineal pain, redness, swelling, or crepitus — Fournier’s gangrene — 911 or immediate ER.
- Severe or recurrent genital yeast, bacterial vaginosis, or balanitis — reassess drug choice; may not require permanent discontinuation.
- New lower-limb wound — in an adult on canagliflozin, reassess drug choice given historical amputation signal (Neal 2017 CANVAS).
- Volume depletion in older adults on loop diuretics — dizziness on standing, lightheadedness, reduced oral intake — reassess dosing and hydration.
- Polyuria masking dehydration — high urine output does not mean adequate hydration; teach visible urine-color checks in warm weather and illness.
- Accidental ingestion in a child — call 1-800-222-1222 (US Poison Control) for immediate guidance.
How this connects to the rest of the site
For the diagnostic and lifestyle context, see diabetes and weight loss, prediabetes and weight loss, type 1 diabetes and weight loss, and gestational diabetes and weight loss. For the cardiorenal picture, see heart failure and weight loss, chronic kidney disease and weight loss, and metabolic syndrome and weight loss. For the anchor diabetes drug this class pairs with, see metformin and weight. For the drug-class comparison, see GLP-1 weight loss overview, GLP-1 medications compared, semaglutide weight loss, tirzepatide weight loss, prescription weight loss medications, and weight loss drug safety. For the older-adult and diet-specific considerations, see weight loss for older adults and low-carb keto diets.
Bottom line
SGLT2 inhibitors produce about 1.8 kg of placebo-adjusted fat-mass loss on average — real but modest, plateauing by 24 weeks, roughly half of what a GLP-1 delivers and about one-fifth of what tirzepatide delivers. That scale change is not why they exist. They are first-line therapy for type 2 diabetes with atherosclerotic cardiovascular disease, for heart failure with reduced or preserved ejection fraction regardless of diabetes, and for chronic kidney disease with eGFR of at least 20 regardless of diabetes because the outcome trials — EMPA-REG, DAPA-HF, EMPEROR-Reduced and Preserved, DELIVER, CREDENCE, DAPA-CKD, EMPA-KIDNEY — are among the strongest in modern internal medicine. Use them for the outcomes, monitor for DKA and mycotic infections, avoid the ketogenic-diet combination, hold peri-procedurally, and treat the modest weight loss as a bonus, not the target.
SGLT2 inhibitors and weight FAQ
Do SGLT2 inhibitors cause weight loss? Yes, modestly — about 1.8 kg placebo-adjusted, mostly fat mass, plateauing by 24 weeks (Cai 2018; Bolinder 2012).
How long until they work? Weight change appears in the first 4 to 8 weeks and plateaus by 24 weeks.
Should I take one for weight loss alone? No — they are not approved as obesity drugs, and a GLP-1 is the correct conversation for weight-focused therapy.
Are they safe? Yes overall, with specific attention to DKA (rare, 0.1% per year), genital mycotic infections (5 to 10%), and rare Fournier’s gangrene (Douros 2020; FDA 2018).
Can I combine with a GLP-1? Yes — the combination is common, additive, and increasingly first-line for T2D with cardiorenal comorbidity.
Can I use one on a keto diet? No — the combination substantially elevates euglycemic DKA risk. Choose one.
When should I stop? Never as a self-directed decision — acute illness, scheduled surgery, eGFR below about 20 for initiation, or a prescriber-coordinated switch are the usual reasons.
Sources
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). New England Journal of Medicine (2015).
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes (CANVAS). New England Journal of Medicine (2017).
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes (DECLARE-TIMI 58). New England Journal of Medicine (2019).
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). New England Journal of Medicine (2019).
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). New England Journal of Medicine (2020).
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved). New England Journal of Medicine (2021).
- Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER). New England Journal of Medicine (2022).
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). New England Journal of Medicine (2019).
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). New England Journal of Medicine (2020).
- The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine (2023).
- Cai X, Yang W, Gao X, et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity (2018).
- Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. Journal of Clinical Endocrinology and Metabolism (2012).
- Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Journal of Clinical Investigation (2016).
- Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care (2015).
- Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Circulation / Lancet Diabetes & Endocrinology (2019–2020).
- Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction (four-pillar HFrEF GDMT). Lancet (2020, updated 2022).
- Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Annals of Internal Medicine (2020).
- American Diabetes Association. Pharmacologic approaches to glycemic treatment and cardiovascular disease and risk management: Standards of Care in Diabetes — 2024 (Sections 9 and 10). Diabetes Care (2024).
- McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal / ESC (2023).
- Kidney Disease: Improving Global Outcomes (KDIGO). 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. KDIGO (2024).
- Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial (EMPULSE / SOLOIST-WHF context). Nature Medicine / NEJM (2021).
- US Food and Drug Administration. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. FDA (2018).